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Introduction

Human kallikrein-related peptidase 6 (KLK6) belongs to a family of secreted serine proteases encoded by 15 homologous genes (KLK1-KLK15) that are important factors in cancer proteolysis. KLK production is abnormal, due to disturbed gene transcription or protein synthesis, or both, in many common human malignancies, highlighting the clinical relevance of KLKs as markers for tumour diagnosis and follow-up
.
KLK6 is present in a myriad of normal tissues including the brain, breast, salivary gland, colon, pancreas, skin, lung and biological fluids [3] [4] [5] [6] . Several studies have found that KLK6 synthesis is abnormal in endocrine-related tumours such as ovarian and uterine carcinomas, and non-cancer diseases, suggesting its utility as a marker [1, [7] [8] [9] [10] . The concentration of KLK6 is also increased in human skin diseases and this concentration is correlated with tumour progression [11] . The clinical use of KLK6 for diagnosing gastric and colon cancer has been discussed recently [11, 12] . While the biological role of KLK6 in these tissues has not yet been identified, several studies have shown how KLK6 contributes to various phases of cancer biology. KLK6 might promote tumour invasion by breaking down extracellular matrix components and stimulating cell proliferation [11, 13, 14] . However, the molecular mechanism by which it stimulates proliferation remains unclear. Despite these findings, little work has been done on KLK6 synthesis and function in lung cancer, the most common and the largest single cause of death from cancer worldwide [6] . , 
We have analysed the concentration and distribution of KLK6 in normal lung tissue and in 46 tissue samples from patients with a primary non-small cell lung cancer (NSCLC). KLK6 was abundant
GAT GGT GAT-3Ј; KLK6 Rev 5Ј-CTG GCT TCT CCT TTG AT-3Ј located on different exons; ␤-actin For 5Ј-GGC GGC ACC ACC ATG TAC CCT-3Ј and ␤-actin Rev 5Ј-AGG GGC CGG ACT CGT CAT ACT-3Ј.
Total RNA from tissues was extracted and reverse transcribed, and KLK6 transcripts quantified by real-time PCR as previously described [15, 16] [20] . Two clones that produced KLK6 and the control parental A549 Flp-In line were selected for further study (Fig. 2A) . Because previous reports suggest that KLK6 production influences cell proliferation [11, 12] , we assessed the growth of both parental and KLK6-producing A549 cells grown at low density for 96 hrs. The two clones producing KLK6 grew significantly faster than the A549 Flp-In cells after 72 hrs in culture (Fig. 2B) 
. The primer sets were designed to target two exons (KLK6 For 5Ј-tga tgg tgg tgc tga gt-3Ј; KLK6 Rev 5Ј-aca gtg gat gga taa gga c-3Ј
Ectopic KLK6 accelerates cell cycle progression in NSCLC lines
We synchronized cells at the end of G1 phase and then released them in the cell cycle to analyse their progression. Starvation and hydroxyurea treatment resulted in the arrest of nearly 85% of the cells in G1 phase (Fig. 3A) . The cell cycle distribution of cells producing KLK6 5 and 8 hrs after release from hydroxyurea was quite different from that of the control line. Significantly more KLK6-producing A549 cells accumulated in the S and G2 phases (Fig. 3B) (Fig. 3C) . There was also a dramatic decrease in the amount of p21, an inhibitor of cyclin-dependent kinases that limit cell cycle progression, in the KLK6-producing cells both 5 and 8 hrs after release from hydroxyurea. (Fig. 3C ). (Fig. 4A) 
KLK6-dependent enhancement of cell cycle progression might be mediated by c-Myc
The dramatic changes in the replication rate and cell cycle progression associated with ectopic KLK6 production indicated that the cell proliferation regulators in KLK6-producing A549 cells were severely disrupted. Therefore, we analysed the expression of c-Myc, a proto-oncogene that is often constitutively overexpressed in lung cancers and promotes cell cycle progression by inducing the genes encoding cyclins D2, -E and -A and repressing cell growth arrest genes like p21 [21-23]. KLK6-producing cells had markedly more c-Myc protein than control cells, both when they were grown in complete medium (data not shown) and when released from hydroxyurea in the cell cycle
High KLK6 expression by NSCLC is associated with poor patient survival
Because our findings suggest that KLK6 overproduction plays a dramatic role in lung cancer development by promoting NSCLC
Fig. 1 KLK6 in tissues from patients with NSCLC but not in NSCLC-derived cell lines. (A) Immunohistochemistry of KLK6 in normal and malignant lung from 46 patients with primary NSCLC using a monoclonal antibody (original magnification: ϫ200; haematoxylin counterstain). KLK6 immunostaining (dark) in the apical region of normal bronchial epithelial cells (thin arrow) and in the cytoplasm of most cancer cells (large arrow). (B) KLK6 production in a panel of NSCLC lines by RT-PCR. Total RNA from NSCLC cell lines was extracted and reverse transcribed. KLK6 and ␤-actin (internal control) mRNAs were amplified from cDNA by PCR and the amplification products were separated on a 1% agarose gel containing ethidium bromide. (1) A549; (2) Calu-1; (3) H23; (4) H460; (5) H520; (6) H522; (7)
H1838
. We analysed the relationship between the amount of KLK6 transcripts and clinical-pathological parameters by univariate analysis. A high KLK6 expression was not correlated with any clinicopathological lung tumour variable (data not shown).
We then studied the association between the KLK6 status and overall patient survival using both Kaplan-Meier survival curves and the Cox proportional hazards regression model. There was a significant correlation between NSCLC cells with a high concentration of KLK6 transcripts and poor patient survival (Fig. 4B and C) [1, 11, 12] . We first demonstrated that several KLKs are produced in the lung and that the synthesis of some of them is deregulated in NSCLC [15, 16, 24] [1, 26, 27] . Recently, hypermethylation of the KLK6 promoter leading to KLK6 gene silencing has been described in metastatic breast cancer cell lines [28] [26, 29] [1, 7, 14, 25, 30] [11, 12] . This agrees well with our finding that ectopic KLK6 dramatically accelerates NSCLC cell growth. The results from our group and others indicate that both [8, 12] .
. Moreover, accumulating evidence highlighted the importance of the interactions between cancer cells and the dynamic microenvironment in which they live (containing soluble and non soluble components of the extracellular matrix and 'activated' non-neoplastic cells) in the regulation of gene expression in cancer cells
In conclusion, we show that KLK6 is a proliferative factor in NSCLC that might act by inducing c-Myc synthesis, which in turn modulates specific components of the cell cycle machinery to promote cell cycle progression. Our present results, together with those from previous reports showing the influence of KLK6 on cancer cell migration and invasion [11, 13] 
